Clinical TrialsZentalis Pharmaceuticals announced that its lead synthetic lethality molecule, WEE1 inhibitor ZN-c3 has been placed on partial clinical hold following the deaths of two patients in one of its monotherapy studies.
Pipeline IssuesZentalis' entire pipeline is centered around the Zn-c3 molecule, which is now facing significant clinical and market challenges.
Stock PerformanceCompany completed 1:20 reverse split, typically a move made by companies facing stock price pressures or to maintain compliance with exchange listing requirements.